Amylyx Pharmaceuticals Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Amylyx Pharmaceuticals, Inc. (AMLX) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-301.7449.27-198.38-87.93-42.28
Depreciation & Amortization0.901.090.490.050.00
Stock Based Compensation33.0437.1621.713.140.24
Change in Working Capital-45.83-65.66-1.644.602.60
Change in Accounts Receivable39.60-24.74-15.310.000.00
Change in Inventory-9.25-73.13-9.770.000.00
Change in Accounts Payable-19.1015.881.850.671.42
Change in Other Working Capital-57.0816.3321.585.231.18
Other Operating Activities145.9925.1848.485.232.74
Net Cash from Operating Activities-167.6511.92-179.87-74.80-36.70
Investing Activities
Capital Expenditures-0.16-1.24-2.53-0.35-0.15
Purchases of Investments-231.99-300.83-236.46-49.050.00
Sales/Maturities of Investments344.00394.12179.41-46.050.00
Other Investing Activities-36.200.000.000.000.00
Net Cash from Investing Activities75.6592.05-238.99-46.41-0.15
Financing Activities
Debt Repayment0.000.000.00-0.260.00
Common Stock Issued2.136.99434.64135.000.05
Common Stock Repurchased0.00-3.320.000.000.00
Other Financing Activities-1.78-3.45-2.85-2.730.00
Net Cash from Financing Activities0.353.54431.79158.5146.82
Summary
Effect of Forex Changes on Cash-0.440.16-0.070.010.00
Net Change in Cash-92.08107.5212.8737.309.98
Cash at Beginning of Period170.9263.2550.3813.070.00
Cash at End of Period78.84170.9263.2550.380.00
Free Cash Flow-167.8010.68-182.40-75.15-36.85
Supplemental Disclosures
Income Taxes Paid0.716.390.030.000.00